GeNeuro Secures Rights to Potential ALS Therapy After Promising Preclinical Studies With NINDS
Swiss biopharma GeNeuro has secured the exclusive worldwide license to the clinical development program for a pHERV-K Env antibody after…
Articles by Diogo Pinto
Chip Technology Identifies Potential Combo Therapy for ALS in Study
Chip technology — much like an organ-on-a-chip that can simulate the workings of tissue or organs  — was used to…
New Method to Create Human Neural Stem Cells Can Regenerate Spine in Rats, Study Shows
Human spinal cord neural stem cells (NSC), created using an innovative method, were seen to regenerate functional neurons in the…
MicroRNA Known to Be Abundant in ALS Patients May Offer Way of Treating Disease, Study Suggests
The microRNA-218 (miR-218), produced at excessive levels by damaged or dying nerve cells, may be a therapeutic target for …
MediciNova Completes Enrollment in ALS MN-166 (Ibudilast) Phase 1/2 Trial
MediciNova has completed enrollment for its Phase 1/2 clinical trial testing the investigational therapy MN-166 (ibudilast) in amyotrophic…
AB Science Not Pursuing Re-examination of Masitinib after EMA’s Negative Opinion on Marketing Approval
AB Science has decided not to seek the re-examination it initially requested after the European Medicines Agency (EMA) issued…
Neural Stem Cell Transplant May Improve Survival, Function in ALS Patients, Trial Results Show
Transplanting human spinal cord-derived neural stem cells (HSSC) into the spine of patients with amyotrophic lateral sclerosis (ALS)Â was found…
New Study Reveals Two Genes Associated with High Risk for ALS
Genetic mutations in two previously unrecognized genes, the microtubule-associated protein tau (MAPT) and BNIP1 genes, are associated with elevated risk…
Specialized Immune Cells May Help Slow ALS Progression, Study Shows
Higher levels of a specialized type of immune cell may help halt the progression of amyotrophic lateral sclerosis (ALS),…